MARKET OUTLOOK

Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available for PAH management. Phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most commonly prescribed first-line treatment; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients?
  • What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
  •  How have Uptravi, Orenitram, and Adempas been integrated into the treatment algorithm and what are their sources of business?
  •  What percentage of PAH patients receive drug therapy within two years of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within two years of diagnosis?
  •  What percentage of PAH patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
  •  What are the product-level compliance and persistency rates among drug-treated PAH patients?

Geographies

United States

Real world data Longitudinal patient-level claims data analysis

Key Drugs Covered

Adcirca, Tracleer, Letairis, Opsumit, Tyvaso, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, sildenafil, epoprostenol Key Analysis provided Brand/therapy usage across longitudinal patient sample Newly diagnosed patient analysis Treatment initiation and progression Line of therapy analysis Combination therapy analysis Source of business for recently treated patients Persistency and compliance analysis Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)
    • Treatment Algorithm | Pulmonary Arterial Hypertension | US | January 2019

Author(s): David Rees, Ph.D

David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.


Related Reports

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., co...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (US)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the tr...

View Details